Copyright
©The Author(s) 2024.
World J Gastrointest Surg. Sep 27, 2024; 16(9): 2829-2841
Published online Sep 27, 2024. doi: 10.4240/wjgs.v16.i9.2829
Published online Sep 27, 2024. doi: 10.4240/wjgs.v16.i9.2829
Table 3 Adverse events
| n (%) | |
| Elevated ALT | |
| Grade 0-2 | 51 (91.07) |
| Grade ≥ 3 | 5 (8.93) |
| Elevated AST | |
| Grade 0-2 | 50 (89.29) |
| Grade ≥ 3 | 6 (10.71) |
| Elevated total bilirubin | |
| Grade 0-2 | 54 (96.43) |
| Grade ≥ 3 | 2 (3.57) |
| Rash | |
| Grade 0-2 | 54 (96.43) |
| Grade ≥ 3 | 2 (3.57) |
| Itching | |
| Grade 0-2 | 56 (100.00) |
| Grade ≥ 3 | 0 |
| Vomiting | |
| Grade 0-2 | 56 (100.00) |
| Grade ≥ 3 | 0 |
| Diarrhea | |
| Grade 0-2 | 56 (100.00) |
| Grade ≥ 3 | 0 |
| Sensory abnormalities | |
| Grade 0-2 | 56 (100.00) |
| Grade ≥ 3 | 0 |
| Thyroiditis | |
| Grade 0-2 | 56 (100.00) |
| Grade ≥ 3 | 0 |
| Abdominal pain | |
| Grade 0-2 | 56 (100.00) |
| Grade ≥ 3 | 0 |
| Gastric ulcer | |
| Grade 0-2 | 56 (100.00) |
| Grade ≥ 3 | 0 |
| Bone marrow suppression | |
| Grade 0-2 | 56 (100.00) |
| Grade ≥ 3 | 0 |
- Citation: Tan BB, Fu Y, Shao MH, Chen HL, Liu P, Fan C, Zhang H. Combined transarterial chemoembolization and tislelizumab for patients with unresectable hepatocellular carcinoma. World J Gastrointest Surg 2024; 16(9): 2829-2841
- URL: https://www.wjgnet.com/1948-9366/full/v16/i9/2829.htm
- DOI: https://dx.doi.org/10.4240/wjgs.v16.i9.2829